Equities

Cardiff Oncology Inc

Cardiff Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.08
  • Today's Change-1.01 / -24.69%
  • Shares traded3.66m
  • 1 Year change+182.57%
  • Beta1.9339
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

  • Revenue in USD (TTM)665.00k
  • Net income in USD-40.88m
  • Incorporated2009
  • Employees31.00
  • Location
    Cardiff Oncology Inc11055 Flintkote AveSAN DIEGO 92121-1220United StatesUSA
  • Phone+1 (858) 952-7570
  • Fax+1 (858) 217-4768
  • Websitehttps://cardiffoncology.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Quantum-Si Inc1.70m-89.35m133.81m159.00--0.5735--78.62-0.6302-0.63020.0121.640.00570.23213.6810,704.40-29.89---30.99--53.41---5,249.65--20.13--0.00------27.55------
P3 Health Partners Inc1.40bn-69.48m133.97m400.00--0.3631--0.0955-0.5821-0.582111.561.031.56--10.973,507,143.00-20.51---110.70--0.62230.1781-13.17-56.93---9.670.2686--20.6770.5878.61---11.20--
INmune Bio Inc42.00k-41.27m135.92m11.00--3.51--3,236.12-2.18-2.180.00221.740.0007--0.02283,818.18-71.48-37.82-94.55-41.86-----98,266.66-14,901.03---34.080.0606---58.56---9.92------
Puma Biotechnology Inc219.14m8.72m141.25m185.0015.742.886.960.64460.1830.1834.561.001.087.077.381,184,557.004.30-12.217.24-20.5373.0878.783.98-11.791.231.990.6474--3.34-1.251,079,450.00--83.41--
Vigil Neuroscience Inc0.00-83.84m141.54m64.00--1.57-----2.12-2.120.002.270.00----0.00-59.07---63.28--------------0.00-------20.98------
Cardiff Oncology Inc665.00k-40.88m143.37m31.00--2.68--215.60-0.9142-0.91420.01491.150.0081--2.1721,451.61-49.98-31.24-57.60-33.56-----6,143.91-7,819.23----0.00--26.425.22-7.07--157.91--
Inovio Pharmaceuticals Inc591.86k-121.64m143.84m122.00--1.49--243.03-5.11-5.110.02483.730.0032--0.66524,851.31-66.32-59.52-84.33-71.29-----20,552.24-4,097.36----0.00---91.89-51.3351.71---31.22--
Context Therapeutics Inc0.00-18.57m146.25m5.00--1.45-----1.06-1.060.001.350.00----0.00-28.46---29.68--------------0.00-------61.53------
Outlook Therapeutics Inc0.00-94.05m149.50m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
CytoDyn Inc0.00-20.53m150.01m9.00---------0.0241-0.02410.00-0.06990.00----0.00-94.20-259.15-----------232,918.20--1.36--------35.70------
Generation Bio Co18.58m-145.47m150.95m174.00--1.44--8.12-2.19-2.190.27971.560.059--56.31106,793.10-46.16-36.96-51.29-39.21-----782.87-8,879.44----0.00----177.317.34--19.61--
Checkpoint Therapeutics Inc78.00k-42.47m151.71m23.00------1,945.00-1.50-1.500.0027-0.3720.0111--2.173,391.30-606.33-142.43---342.79-----54,444.87-6,554.97---------46.35-50.6117.21------
Repare Therapeutics Inc66.52m-84.05m152.38m179.00--0.8723--2.29-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
Candel Therapeutics Inc0.00-49.99m154.97m42.00---------1.70-1.700.00-0.3210.00----0.00-117.35---158.61-------------32.702.36---100.00---101.87------
Data as of Nov 08 2024. Currency figures normalised to Cardiff Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

17.97%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20242.42m5.19%
The Vanguard Group, Inc.as of 30 Jun 20242.09m4.48%
Geode Capital Management LLCas of 30 Jun 2024910.68k1.96%
SSgA Funds Management, Inc.as of 30 Jun 2024805.02k1.73%
MAI Capital Management LLCas of 30 Jun 2024658.79k1.42%
Morgan Stanley & Co. LLCas of 30 Jun 2024451.09k0.97%
Marshall Wace LLPas of 30 Jun 2024298.83k0.64%
Assenagon Asset Management SA (Germany)as of 30 Sep 2024270.52k0.58%
Millennium Management LLCas of 30 Jun 2024239.61k0.52%
William Blair Investment Management LLCas of 30 Jun 2024227.63k0.49%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.